---
schema_version: "secwatch.filing_event.v1"
accession: "0001297184-26-000041"
form_type: "8-K"
ticker: "AMPH"
cik: "0001297184"
company_name: "Amphastar Pharmaceuticals, Inc."
filed_at: "2026-07-08T00:03:50+00:00"
generated_at: "2026-07-08T10:05:22.464867+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Amphastar subsidiary IMS receives FDA warning letter for CGMP violations at South El Monte facility

## Summary
- Warning letter dated July 2, 2026, follows December 2025 FDA inspection of IMS's South El Monte, CA facility.
- Cites violations of current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals.
- FDA does not direct IMS to cease or restrict products from the facility; no further recall required at this time.
- IMS must submit initial response within 15 working days and provide a risk assessment and remediation plan.
- Company is evaluating impact; additional regulatory or legal action possible if deficiencies are not resolved.

## SEC filing metadata
- accession: 0001297184-26-000041
- form_type: 8-K
- ticker: AMPH
- cik: 0001297184
- company_name: Amphastar Pharmaceuticals, Inc.
- filed_at: 2026-07-08T00:03:50+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1297184/000129718426000041/0001297184-26-000041-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1297184/000129718426000041/amph-20260702x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001297184-26-000041
- JSON: https://secwatch.observer/filing/0001297184-26-000041.json
- Plain text: https://secwatch.observer/filing/0001297184-26-000041.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.